nach oben

International Journal of Clinical Oncology

Erschienen in:

14.10.2019 | Original Article

FDG-PET reflects tumor viability on SUV in colorectal cancer liver metastasis

verfasst von: Akira Watanabe, Norifumi Harimoto, Takehiko Yokobori, Kenichiro Araki, Norio Kubo, Takamichi Igarashi, Mariko Tsukagoshi, Norihiro Ishii, Takahiro Yamanaka, Tadashi Handa, Tetsunari Oyama, Tetsuya Higuchi, Ken Shirabe

Erschienen in: International Journal of Clinical Oncology | Ausgabe 2/2020

Einloggen, um Zugang zu erhalten

Abstract

Background

Liver resection is the most effective procedure for colorectal cancer liver metastasis (CRLM); however, early recurrence is an important problem that affects the postoperative prognoses of patients with CRLM. We previously suggested a therapeutic algorithm for CRLM using fluorodeoxyglucose-positron emission tomography (FDG-PET) and revealed the applicability of FDG-PET in predicting the prognosis after liver resection of CRLM. In this study, we assessed the correlation between FDG-PET and biological viability such as proliferation or metabolic activity.

Methods

We retrospectively evaluated 61 patients who underwent hepatectomy for CRLM. We assessed hypoxia inducible factor-1α (HIF-1α), pyruvate kinase isozyme M2 (PKM2), glucose transporter 1 (GLUT1), and Ki-67 expression via immunohistochemistry and evaluated the correlation between standardized uptake value (SUV) and these factors.

Results

High HIF-1α, PKM2, and GLUT1 expression were positively correlated with high SUV expression (P = 0.0444, 0.0296, and 0.0245, respectively). Ki-67 and SUV were also positively correlated (P = 0.00164). HIF-1α expression and PKM2 expression were significantly correlated (P = 0.0430), and PKM2 expression and GLUT1 expression were extremely significantly correlated (P < 0.0001).

Conclusion

SUV reflected tumor proliferation or metabolic factors in CRLM. FDG-PET could be a useful modality for assessing tumor viability and may provide useful information regarding the appropriate treatment strategy for CRLM.

Nur mit Berechtigung zugänglich

Akgül Ö, Çetinkaya E, Ersöz Ş et al (2014) Role of surgery in colorectal cancer liver metastases. World J Gastroenterol 20:6113–6122CrossRef

McNally SJ, Parks RW (2013) Surgery for colorectal liver metastases. Dig Surg 30:337–347CrossRef

Allard MA, Adam R, Giuliante F et al (2017) Long-term outcomes of patients with 10 or more colorectal liver metastases. Br J Cancer 117:604–611CrossRef

Simmonds PC, Primrose JN, Colquitt JL et al (2006) Surgical resection of hepatic metastases from colorectal cancer: a systematic review of published studies. Br J Cancer 94:982–999CrossRef

Fong Y, Fortner J, Sun RL et al (1999) Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 230:309–318 (discussion 318–321) CrossRef

Hadden WJ, de Reuver PR, Brown K et al (2016) Resection of colorectal liver metastases and extra-hepatic disease: a systematic review and proportional meta-analysis of survival outcomes. HPB (Oxford) 18:209–220CrossRef

Matias M, Casa-Nova M, Faria M et al (2015) Prognostic factors after liver resection for colorectal liver metastasis. Acta Med Port 28:357–369CrossRef

Beppu T, Sakamoto Y, Hasegawa K et al (2012) A nomogram predicting disease-free survival in patients with colorectal liver metastases treated with hepatic resection: multicenter data collection as a Project Study for Hepatic Surgery of the Japanese Society of Hepato-Biliary-Pancreatic Surgery. J Hepatobiliary Pancreat Sci 19:72–84CrossRef

Angelsen JH, Viste A, Loes IM et al (2015) Predictive factors for time to recurrence, treatment and post-recurrence survival in patients with initially resected colorectal liver metastases. World J Surg Oncol 13:328CrossRef

10.

Nagashima I, Takada T, Adachi M et al (2006) Proposal of criteria to select candidates with colorectal liver metastases for hepatic resection: comparison of our scoring system to the positive number of risk factors. World J Gastroenterol 12:6305–6309CrossRef

11.

Wu Y, Li C, Zhao J et al (2016) Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios predict chemotherapy outcomes and prognosis in patients with colorectal cancer and synchronous liver metastasis. World J Surg Oncol 14:289CrossRef

12.

Willowson KP, Hayes AR, Chan DLH et al (2017) Clinical and imaging-based prognostic factors in radioembolisation of liver metastases from colorectal cancer: a retrospective exploratory analysis. EJNMMI Res 7:46CrossRef

13.

Watanabe A, Harimoto N, Araki K et al (2018) A new strategy based on fluorodeoxyglucose-positron emission tomography for managing liver metastasis from colorectal cancer. J Surg Oncol 118:1088–1095CrossRef

14.

Kato H, Kuwano H, Nakajima M et al (2002) Comparison between positron emission tomography and computed tomography in the use of the assessment of esophageal carcinoma. Cancer 94:921–928CrossRef

15.

Takahashi S, Kuroki Y, Nasu K et al (2006) Positron emission tomography with F-18 fluorodeoxyglucose in evaluating colorectal hepatic metastasis down-staged by chemotherapy. Anticancer Res 26:4705–4711PubMed

16.

Moulton CA, Gu CS, Law CH et al (2014) Effect of PET before liver resection on surgical management for colorectal adenocarcinoma metastases: a randomized clinical trial. JAMA 311:1863–1869CrossRef

17.

Muralidharan V, Kwok M, Lee ST et al (2012) Prognostic ability of 18F-FDG PET/CT in the assessment of colorectal liver metastases. J Nucl Med 53:1345–1351CrossRef

18.

Lee HS, Kim HO, Hong YS et al (2014) Prognostic value of metabolic parameters in patients with synchronous colorectal cancer liver metastasis following curative-intent colorectal and hepatic surgery. J Nucl Med 55:582–589CrossRef

19.

Riedl CC, Akhurst T, Larson S et al (2007) 18F-FDG PET scanning correlates with tissue markers of poor prognosis and predicts mortality for patients after liver resection for colorectal metastases. J Nucl Med 48:771–775CrossRef

20.

Binderup T, Knigge UP, Federspiel B et al (2013) Gene expression of glucose transporter 1 (GLUT1), hexokinase 1 and hexokinase 2 in gastroenteropancreatic neuroendocrine tumors: correlation with F-18-fluorodeoxyglucose positron emission tomography and cellular proliferation. Diagnostics (Basel) 3:372–384CrossRef

21.

Sato J, Kitagawa Y, Yamazaki Y et al (2013) 18F-fluoromisonidazole PET uptake is correlated with hypoxia-inducible factor-1alpha expression in oral squamous cell carcinoma. J Nucl Med 54:1060–1065CrossRef

22.

Strasberg SM (2005) Nomenclature of hepatic anatomy and resections: a review of the Brisbane 2000 system. J Hepatobiliary Pancreat Surg 12:351–355CrossRef

23.

Kanda Y (2013) Investigation of the freely available easy-to-use software 'EZR' for medical statistics. Bone Marrow Transplant 48:452–458CrossRef

24.

Chun YS, Vauthey JN, Boonsirikamchai P et al (2009) Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal liver metastases. JAMA 302:2338–2344CrossRef

25.

Shindoh J, Loyer EM, Kopetz S et al (2012) Optimal morphologic response to preoperative chemotherapy: an alternate outcome end point before resection of hepatic colorectal metastases. J Clin Oncol 30:4566–4572CrossRef

26.

Hosseini-Nik H, Fischer SE, Moulton CA et al (2016) Diffusion-weighted and hepatobiliary phase gadoxetic acid-enhanced quantitative MR imaging for identification of complete pathologic response in colorectal liver metastases after preoperative chemotherapy. Abdom Radiol (NY) 41:231–238CrossRef

27.

Meng X, Li H, Kong L et al (2016) MRI In rectal cancer: correlations between MRI features and molecular markers Ki-67, HIF-1alpha, and VEGF. J Magn Reson Imaging 44:594–600CrossRef

28.

Deng SM, Zhang W, Zhang B et al (2015) Correlation between the uptake of 18F-fluorodeoxyglucose (18F-FDG) and the expression of proliferation-associated antigen Ki-67 in cancer patients: a meta-analysis. PLoS One 10:e0129028CrossRef

29.

Shannon AM, Bouchier-Hayes DJ, Condron CM et al (2003) Tumour hypoxia, chemotherapeutic resistance and hypoxia-related therapies. Cancer Treat Rev 29:297–307CrossRef

30.

Bos R, van der Groep P, Greijer AE et al (2003) Levels of hypoxia-inducible factor-1alpha independently predict prognosis in patients with lymph node negative breast carcinoma. Cancer 97:1573–1581CrossRef

31.

Schindl M, Schoppmann SF, Samonigg H et al (2002) Overexpression of hypoxia-inducible factor 1alpha is associated with an unfavorable prognosis in lymph node-positive breast cancer. Clin Cancer Res 8:1831–1837PubMed

32.

Luo W, Hu H, Chang R et al (2011) Pyruvate kinase M2 is a PHD3-stimulated coactivator for hypoxia-inducible factor 1. Cell 145:732–744CrossRef

33.

Ouyang Y, Li H, Bu J et al (2016) Hypoxia-inducible factor-1 expression predicts osteosarcoma patients' survival: a meta-analysis. Int J Biol Markers 31:e229–e234CrossRef

34.

Huang C, Huang Z, Bai P et al (2018) Expression of pyruvate kinase M2 in human bladder cancer and its correlation with clinical parameters and prognosis. Onco Targets Ther 11:2075–2082CrossRef

35.

Yang Y, Wu K, Liu Y et al (2017) Prognostic significance of metabolic enzyme pyruvate kinase M2 in breast cancer: a meta-analysis. Medicine (Baltimore) 96:e8690CrossRef

36.

Masoud GN, Li W (2015) HIF-1α pathway: role, regulation and intervention for cancer therapy. Acta Pharm Sin B 5:378–389CrossRef

37.

Yang W, Zheng Y, Xia Y et al (2012) ERK1/2-dependent phosphorylation and nuclear translocation of PKM2 promotes the Warburg effect. Nat Cell Biol 14:1295–1304CrossRef

Titel: FDG-PET reflects tumor viability on SUV in colorectal cancer liver metastasis
verfasst von: Akira Watanabe
Norifumi Harimoto
Takehiko Yokobori
Kenichiro Araki
Norio Kubo
Takamichi Igarashi
Mariko Tsukagoshi
Norihiro Ishii
Takahiro Yamanaka
Tadashi Handa
Tetsunari Oyama
Tetsuya Higuchi
Ken Shirabe
Publikationsdatum: 14.10.2019
Verlag: Springer Singapore
Erschienen in: International Journal of Clinical Oncology / Ausgabe 2/2020
Print ISSN: 1341-9625
Elektronische ISSN: 1437-7772
DOI: https://doi.org/10.1007/s10147-019-01557-0

Springer Medizin

FDG-PET reflects tumor viability on SUV in colorectal cancer liver metastasis